LivFul
- Industry
- Biotechnology
- Founded Year
- 2015
- Headquarters
- Alpharetta, Georgia, United States
- Employee Count
- 34
Key People
- Michael Norman - Chairman and CEO
- Hogan Bassey - Founder and Chief Access Officer
- Andy Mahler - Co-Founder, Chief Impact Officer & CEO of LivFul North America
- Matt Elsberry - Co-Chief Executive Officer
- John Manwell - Chief Operations Officer
- Francis Yip - Chief Commercial Officer
- Daniel Oppong - Managing Director - Africa
- Ivan De Oliveira - Managing Director - Latin America
- Thomas Dooley - Chief Scientific Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in biotechnology and healthcare.
The leadership team includes individuals with significant experience in biotechnology and healthcare sectors, enhancing the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: LivFul addresses critical health issues in underserved populations.
By targeting mosquito-borne diseases and other health challenges prevalent in underserved regions, LivFul meets a pressing clinical need, potentially saving numerous lives.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for insect repellents and health solutions is competitive.
While LivFul offers innovative products, the market for insect repellents and health solutions includes several established companies, posing competitive challenges.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of insect repellents involves manageable technical challenges.
The company's focus on insect repellents and health solutions involves technical challenges that are well-understood and manageable within the industry.
- Patent
-
Aspect: Strong
Summary: LivFul holds patents for its proprietary technologies.
LivFul's proprietary technologies, such as STAYTEC, are protected by patents, providing a competitive edge and potential barriers to entry for competitors.
- Financing
-
Aspect: Medium
Summary: LivFul has secured multiple funding rounds totaling over $24 million.
LivFul's funding history demonstrates investor confidence; however, continued financial support will be essential to scale operations and expand market reach.
- Regulatory
-
Aspect: 510k/PMA
Summary: LivFul's products require regulatory approvals for market entry.
The company's products, such as insect repellents, must comply with regulatory standards, which can be time-consuming and resource-intensive.
Opportunity Rollup
- Odds of Success
- 4
- Peak Market Share
- 5.3
- Segment CAGR
- 5.4%
- Market Segment
- Insect Repellents
- Market Sub Segment
- Mosquito-Borne Disease Prevention
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.80 |
| 3 | 1.85 |
| 4 | 3.71 |
| 5 | 5.30 |
Key Takeaway
LivFul's innovative approach to health solutions positions it well in a growing market, but strategic efforts are needed to navigate competition and regulatory challenges.